| Effect | Decrease |
| Trial Design | Cohort |
| Trial Length | 2-4 Weeks |
| Number of Subjects | 10 |
| Sex | Both Genders |
| Age Range | 30-44, 45-64 |
| Body Types | Average |
In persons with HIV who were already on anti-viral therapy, controlling the diet and then supplementing TTA (1,000mg in four divided doses for four weeks) exerted hypolipidemic and anti-inflammatory properties yet did not influence viral loads in the tested immune cells. No placebo group was used.
The decrease in apolipoprotein B was trending to, but did not reach, statistical significance (P = 0.08). The decrease in triglycerides seen was not additive with the dietary treatment and was not seen as evidence for the efficacy of TTA.
